tiprankstipranks
Trending News
More News >
Nipro Corporation (JP:8086)
:8086

Nipro (8086) AI Stock Analysis

Compare
0 Followers

Top Page

JP

Nipro

(Frankfurt:8086)

Rating:57Neutral
Price Target:
¥1,324.00
▲(0.57%Upside)
The overall score reflects solid revenue growth and strong operating cash flow, offset by challenges in profitability, high leverage, and an overvalued stock price. The technical analysis suggests a bearish trend, reinforcing a cautious outlook.

Nipro (8086) vs. iShares MSCI Japan ETF (EWJ)

Nipro Business Overview & Revenue Model

Company DescriptionNipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses. The company's Medical Device business develops, manufactures, and sells various disposable medical products comprising renal, intervention and anesthesiology, injection and infusion, dialysis, cardiopulmonary, diabetic, and cell cultures products; and sells artificial organ-related products, and generic and kit products. Its Pharmaceutical business provides pharmaceutical combination products, including dual chamber bags, pre-filled syringes, and half-type kits; and contract manufacturing services for orally administered drugs, injectables, and external preparations. The company's Pharma Packaging business offers glass vials, ampoules, syringes, and cartridges; glass tubes; glass forming machinery; glass bulbs for vacuum flasks; and other parts of pharmaceutical packaging, such as rubber plugs. Its Other business provides thermostable enzymes for clinical chemistry. The company also offers business management services. Nipro Corporation serves customers in Japan, the Americas, Europe, and rest of Asia. The company was founded in 1947 and is headquartered in Osaka, Japan.
How the Company Makes MoneyNipro Corporation generates revenue through the sale of its medical devices, pharmaceuticals, and pharmaceutical packaging products. The company operates through various segments, with a significant portion of its revenue coming from medical-related products such as dialysis machines and disposables. Additionally, Nipro earns from its pharmaceutical division which produces injectable drugs and oral medications, and its pharma packaging segment which offers services and products for drug delivery systems. The company's global reach and partnerships with healthcare facilities and providers contribute to its revenue generation. Nipro also invests in research and development to enhance its product offerings and maintain competitive advantage in the healthcare industry.

Nipro Financial Statement Overview

Summary
Nipro shows solid revenue growth and stable gross margins but struggles with net profitability and high leverage. Operating cash flow is robust, yet negative free cash flow indicates capital management challenges.
Income Statement
75
Positive
Nipro has demonstrated consistent revenue growth with a notable increase of 9.83% from 2024 to 2025. Gross profit margins have remained stable, reflecting strong cost management. However, the net profit margin has decreased due to a significant drop in net income, highlighting potential challenges in managing operating expenses or increased costs elsewhere.
Balance Sheet
68
Positive
The company's debt-to-equity ratio indicates high leverage, which could pose risks in economic downturns. Although total assets have increased, stockholder equity growth has not kept pace, resulting in a moderate equity ratio. Return on equity is low, suggesting challenges in generating efficient returns for shareholders.
Cash Flow
65
Positive
Nipro's free cash flow has shown improvement but remains negative, indicating ongoing challenges in generating surplus cash after capital expenditures. The operating cash flow to net income ratio is strong, suggesting that the company generates healthy operating cash relative to earnings, despite reduced net income.
BreakdownTTMMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue626.93B644.59B586.78B545.20B494.79B455.56B
Gross Profit184.97B190.88B171.32B163.45B149.27B138.84B
EBITDA87.02B92.58B84.62B66.47B70.05B70.25B
Net Income5.07B5.11B11.11B4.57B13.46B14.21B
Balance Sheet
Total Assets1.15T1.17T1.11T1.03T930.32B854.40B
Cash, Cash Equivalents and Short-Term Investments85.49B106.67B99.67B89.68B95.34B90.27B
Total Debt665.76B632.07B635.69B605.93B564.85B545.28B
Total Liabilities874.79B858.94B840.03B785.23B730.46B680.35B
Stockholders Equity233.24B252.45B232.66B206.32B185.24B161.02B
Cash Flow
Free Cash Flow0.00-8.15B-21.33B-74.44B-11.59B14.91B
Operating Cash Flow0.0068.46B72.94B10.39B68.21B66.09B
Investing Cash Flow0.00-71.88B-87.08B-71.74B-78.43B-45.07B
Financing Cash Flow0.005.38B22.14B43.08B10.30B-22.06B

Nipro Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1316.50
Price Trends
50DMA
1278.65
Positive
100DMA
1297.27
Positive
200DMA
1346.06
Negative
Market Momentum
MACD
5.61
Negative
RSI
61.25
Neutral
STOCH
87.89
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:8086, the sentiment is Positive. The current price of 1316.5 is above the 20-day moving average (MA) of 1273.77, above the 50-day MA of 1278.65, and below the 200-day MA of 1346.06, indicating a neutral trend. The MACD of 5.61 indicates Negative momentum. The RSI at 61.25 is Neutral, neither overbought nor oversold. The STOCH value of 87.89 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:8086.

Nipro Peers Comparison

Overall Rating
UnderperformOutperform
Sector (59)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
€161.81B28.294.78%2.70%20.53%-75.16%
74
Outperform
¥636.96B60.487.09%1.03%17.38%-30.54%
70
Outperform
$3.72T31.888.56%1.05%12.40%10.46%
69
Neutral
$1.57T29.2311.84%1.20%10.21%8.55%
66
Neutral
¥1.90T16.3915.47%1.18%6.53%-46.94%
59
Neutral
£5.86B9.18-57.69%4.67%15.15%-9.83%
57
Neutral
¥214.72B41.992.07%3.04%9.85%-53.97%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:8086
Nipro
1,304.00
68.89
5.58%
JP:7716
Nakanishi
1,870.00
-652.38
-25.86%
JP:6869
Sysmex
2,445.50
-44.37
-1.78%
JP:7747
Asahi Intecc Co
2,297.00
105.55
4.82%
JP:4543
Terumo
2,481.00
-240.75
-8.85%
JP:7733
Olympus
1,673.00
-909.65
-35.22%

Nipro Corporate Events

Nipro Corporation Transfers Real Estate Interest for Financial Gain
Jun 23, 2025

Nipro Corporation has announced the transfer of beneficial interest in a domestic real estate trust, specifically land located in Hamura, Tokyo, to Hulic Co., Ltd. This strategic move aims to enhance asset efficiency and strengthen Nipro’s financial base, resulting in an extraordinary gain of ¥4.1 billion. The property will continue to be utilized under a lease agreement, ensuring no disruption to Nipro’s operations. The transaction is expected to positively impact Nipro’s financial performance in the fiscal year ending March 2026, with potential revisions to be disclosed as necessary.

The most recent analyst rating on (JP:8086) stock is a Sell with a Yen1100.00 price target. To see the full list of analyst forecasts on Nipro stock, see the JP:8086 Stock Forecast page.

Nipro Corporation Proposes Amendments to Strengthen Governance
May 22, 2025

Nipro Corporation’s Board of Directors has proposed amendments to its Articles of Incorporation, aiming to enhance corporate governance and operational flexibility. Key changes include revising the Board’s operational procedures, clarifying director roles, increasing the number of Audit & Supervisory Board members, and allowing the Board to make decisions on surplus dividends. These amendments are expected to strengthen Nipro’s governance framework and improve management efficiency, potentially impacting stakeholders positively by fostering a more agile and responsive corporate structure.

The most recent analyst rating on (JP:8086) stock is a Sell with a Yen1100.00 price target. To see the full list of analyst forecasts on Nipro stock, see the JP:8086 Stock Forecast page.

Nipro Corporation Reports Significant Foreign Exchange Loss
May 12, 2025

Nipro Corporation has reported a significant increase in non-operating expenses due to a foreign exchange loss of 5.381 billion yen for the fiscal year ending March 2025. This loss, primarily caused by the rapid appreciation of the yen affecting USD-denominated receivables, has been reflected in their consolidated financial results, indicating potential challenges in their financial performance and market positioning.

Nipro Corporation Reports Financial Discrepancy and Announces Dividend Distribution
May 12, 2025

Nipro Corporation announced a discrepancy between its forecasted and actual financial results for the fiscal year ending March 31, 2025, with lower-than-expected profits due to increased inventories, reorganization efforts, and a challenging economic environment. The company also resolved to distribute dividends of surplus, which will be addressed at the upcoming shareholders’ meeting, reflecting its ongoing commitment to shareholder value despite financial challenges.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 02, 2025